Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05048238 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus
A Phase 1 study of Cutaneous Lupus, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
- 2
- Study locations
NCT05048238 is a Phase 1 study of Cutaneous Lupus that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 7 participants, below the 671-participant average among 3 other Cutaneous Lupus trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05048238, a Phase 1 study of Cutaneous Lupus, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a single-arm, multi-site, proof-of-concept study that will evaluate the treatment of 10 participants with cutaneous lupus erythematosus (CLE) with Tofacitinib.
Conditions Studied
Interventions
- DRUG Tofacitinib
Study Locations (2)
Massachusetts
- University of Massachusetts Medical School - Worcester
Michigan
- University of Michigan Health System: Department of Internal Medicine, Division of Rheumatology - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2022-09-30 |
| Est. Completion | 2024-02-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05048238
The ClinicalTrials.gov registry entry for NCT05048238 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 671-participant average among 3 other Cutaneous Lupus trials with a reported enrollment target (99% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cutaneous Lupus appearing as the primary indexed condition, and to 1 intervention - of which Tofacitinib is the first listed.
NCT05048238 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Michigan.
Frequently Asked Questions
What is clinical trial NCT05048238 about?
NCT05048238 is a clinical study titled "Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus". This is a single-arm, multi-site, proof-of-concept study that will evaluate the treatment of 10 participants with cutaneous lupus erythematosus (CLE) with Tofacitinib.
What is the current status of trial NCT05048238?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2022-09-30. Estimated completion is 2024-02-29.
What conditions does trial NCT05048238 study?
This clinical trial studies the following conditions: Cutaneous Lupus.
What interventions are being tested in trial NCT05048238?
The interventions under investigation include: Tofacitinib (DRUG).
Who is sponsoring clinical trial NCT05048238?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05048238 being conducted?
This trial has 2 study locations across Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cutaneous Lupus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.